were significantly higher than the maximum cefotaxime levels, the authors were not able to demonstrate noticeable clinical differences between daily treatment with once 2 g ceftriaxone and 3 times 2 g cefotaxime. Soriano and the Spanish study group evaluated single daily dose ceftriaxone treatment in 125 patients with microbio-logically proven severe bacteremia. In 36% of these patients the bacteremia was nosocomially acquired. 84.8% of the patients recovered completely. Therefore, ceftriaxone was regarded by the authors as a useful treatment for severe bacteremic infections. Barradas et al. compared the efficacy of 2-gram doses of ceftriaxone and cefotaxime in bacterial pneumonia. They found a statistically significant difference [90.5% versus 73.7% (p < 0.05)] in favour of ceftriaxone, in spite of the fact that ceftriaxone was administered once daily and cefotaxime 3 times daily. In conclusion, seven papers were presented during the workshop, reporting on the results obtained with the third-generation cephalosporin ceftriaxone in the once-daily treatment of severe infections. A wide variety of indications was dealt with, including septicemia, febrile episodes in cancer patients, bacterial infections in cirrhotic patients, nosocomial pneumonia and acute neurological manifestations in Lyme borreliosis. The reference drugs were cetotaxime, imipenem plus cilastatin and ceftazidime plus amikacin, given 3-4 times daily. Overall, the investigators judged ceftriaxone given once daily to be well tolerated and at least as effective as the reference drugs given in multiple daily doses. These results are in accordance with those published to date on the basis of worldwide clinical experience with patients treated with ceftriaxone ( fig. 1) 
